Key Takeaways Sanofi gained FDA approval for Wayrilz to treat persistent or chronic immune thrombocytopenia.Approval based on LUNA 3 study data showing sustained platelet gains and symptom improvement.Wayrilz is also in studies for IgG4-RD and wAIHA, with orphan drug designations from the FDA.Sanofi (SNY) announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient r ...